Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2025)
Historic Total Current Liabilities for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $27.8 million.
- Janux Therapeutics' Total Current Liabilities rose 6206.25% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 6206.25%. This contributed to the annual value of $17.5 million for FY2024, which is 3395.99% up from last year.
- Latest data reveals that Janux Therapeutics reported Total Current Liabilities of $27.8 million as of Q3 2025, which was up 6206.25% from $21.4 million recorded in Q2 2025.
- Janux Therapeutics' 5-year Total Current Liabilities high stood at $27.8 million for Q3 2025, and its period low was $9.2 million during Q2 2021.
- Moreover, its 5-year median value for Total Current Liabilities was $15.3 million (2023), whereas its average is $15.4 million.
- As far as peak fluctuations go, Janux Therapeutics' Total Current Liabilities surged by 30229.49% in 2021, and later crashed by 3551.72% in 2024.
- Janux Therapeutics' Total Current Liabilities (Quarter) stood at $12.8 million in 2021, then grew by 28.99% to $16.5 million in 2022, then dropped by 21.05% to $13.0 million in 2023, then surged by 33.96% to $17.5 million in 2024, then skyrocketed by 59.41% to $27.8 million in 2025.
- Its Total Current Liabilities was $27.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $17.5 million in Q1 2025.